Last year, the FDA gave accelerated approval of the antibody aducanumab (marketed as Aduhelm by Biogen) for the treatment of Alzheimer’s disease. The approval was based solely on a presumed reduction in the amount of the protein “amyloid” in the brain as assessed by amyloid-PET scans and without evidence of significant clinical effect.